Making chemotherapy kinder for childhood leukaemia

September 14, 2018 by Dr Rosanna Jackson, Cancer Research UK
Making chemotherapy kinder for childhood leukaemia
Dr Rosanna Jackson. Credit: Cancer Research UK

Chemotherapy often gets a bad reputation – mainly down to the side effects it can cause.

This bad reputation can be hard to shake off. And it often stops people hearing the vast improvements that have been made in how chemotherapy is used.

I can remember first learning about chemotherapy in my undergraduate pharmacology degree. I couldn't believe how much research has gone into making it better for patients. And although this research rarely hits the headlines, a small change in how a patient is treated can make a real difference to both their chance of survival and quality of life.

So when it came to choosing what to research for my Ph.D., I chose a project aiming to improve existing treatments.

I was fortunate enough to be offered a Cancer Research UK-funded Ph.D. position at Newcastle University, looking at ways to personalise the use of drugs for a type of blood often diagnosed in , called (ALL).

Throughout my Ph.D., I've had the privilege of learning from world renowned cancer researchers. In this post, I'm going to cover some of the progress these researchers have made in treating children with ALL with chemotherapy.

Why childhood ALL?

Childhood ALL is a shining example of the progress researchers have made in how we use chemotherapy. In the early 1970s, only around 3 in 10 children with ALL were cancer free 5 years after treatment. Today, this figure has risen to nearly 9 in 10 children.

But a large part of this improvement has been because doctors have used higher doses of drugs. Over time, this increased intensity has led to an increase in children experiencing side effects from their treatment, many of which are permanent.

The focus now is to find ways to make chemotherapy kinder to children with ALL, and also cure the small number of children that still aren't today.

Getting personal

As with all cancer types, things are often more complicated with ALL than they seem. The disease can vary significantly from one patient to another and form many sub groups. These sub groups are usually defined by differences in the DNA inside the cancer cells. And these DNA changes can dramatically affect how the cells behave, and how sensitive they are to chemotherapy.

It's these genetic differences that are helping doctors to tailor treatment to individual patients.

This means that from the outset, we can give patients the right treatment intensity for their particular type of ALL.

Now, instead of giving all patients enough chemotherapy to cure the most aggressive types of ALL, which brings with it the possibility of more side effects, we can use genetics to identify the children with less aggressive disease and only give them the treatment they need.

An adaptive treatment plan

Scientists are also continuing to improve techniques to measure how many cancer cells have survived treatment.

Hospitals and research labs like mine work together to test patients' samples for ALL cells. We do this by detecting differences in tiny features of the cells. By using these new techniques, we can now identify less than one ALL cell in 10,000 normal cells .

This can help doctors to adapt the dose of chemotherapy based on how a child is responding to treatment, avoiding unnecessary side effects.

Scientists have found that counting the number of ALL cells in a blood sample after 28 days of treatment is the best way to predict how well a patient will do compared to other patients with the same type of ALL.

And UK researchers found that if a child has small numbers of cancer cells in their blood after 28 days of chemotherapy, they could be given less treatment from that point onwards and still have the same good chance of survival.

Now, treatment of children with ALL in the UK is adapted based on this initial response to therapy.

And we're continuously looking for more ways to improve therapy. During my Ph.D. I was involved in looking at whether a change in the way a drug called dexamethasone is given could help reduce side effects.

Dexamethasone is a crucial anti-leukaemia drug given to children at the start of their treatment, but it can cause side effects like increased risk of infection, altered sugar processing and long-term damage to bones.

Right now, children are given a course of dexamethasone for 28 days. Because side effects can sometimes happen when dexamethasone is taken for long periods of time, scientists predicted that giving higher doses for fewer days would decrease side effects, but still have the same effect on the .

To test this, we compared giving a higher dose for 14 days to the standard way of giving dexamethasone over 28 days. I measured the levels of dexamethasone in patient's blood to compare the two groups.

Unfortunately, the shorter dose didn't reduce side effects, so doctors are continuing to give the standard dose. But interestingly, my results showed that although children on each dose were given the same amount of dexamethasone for their size, the concentration in their bodies varied dramatically.

It suggests that children are processing the drug differently, which may help to explain why no difference was seen between the two doses.

Although this part of the trial didn't help to reduce side effects, it helped us to better understand how works in ALL treatment. This is important for any future changes researchers make to therapy. And it's just one of the adaptions scientists are testing to try and lower the chance of children having in a current UK trial.

The future

The fine-tuning of over the decades has dramatically improved survival for patients. And new treatments are providing options for the small number of children whose cancer doesn't respond to current therapies. In August this year, NHS England announced that a personalised cancer immunotherapy will be offered to some children and young adults with ALL.

Now we're working to improve the quality of life for patients as they grow up and continue their lives. The importance of this should never be underestimated.

Unfortunately, this same progress hasn't yet been possible for all cancers. Our aim is to continue to develop established medicines alongside the use of new targeted therapies, to give all cancer patients the best chance of survival, and make those saved years the best they can be.

Explore further: Extended chemo extends life for children with rare cancer

Related Stories

Extended chemo extends life for children with rare cancer

June 4, 2018
(HealthDay)—Children suffering from rhabdomyosarcoma, a rare cancer of the muscle tissue, may have better chances for a cure if they have extended chemotherapy, a new study finds.

Novel drug cocktails strengthen targeted cancer therapies while lessening side effects

August 1, 2018
Mount Sinai researchers have discovered that certain drug cocktails help targeted therapies attack cancer more efficiently while lessening common side effects, according to a study published today in Cancer Research.

New treatment helps avoid deafness in child chemotherapy patients

June 21, 2018
An international trial has found that a medicine commonly used to treat poisoning is effective in reducing deafness in children receiving chemotherapy for cancer.

New drug technology may improve treatment options for aggressive types of breast cancer

June 20, 2018
Purdue University researchers have developed a new technology that may change how one of the most aggressive types of breast cancer is treated.

New antibody drug conjugate could be used to target treatment-resistant childhood leukaemia

May 18, 2017
Researchers at The University of Manchester have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, ...

New drug halves hearing loss in children following cancer treatment

June 20, 2018
Giving the drug sodium thiosulphate after chemotherapy reduces hearing loss in children treated for liver cancer, according to findings published in the New England Journal of Medicine today.

Recommended for you

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.